Jan 09, 2023 / 11:45PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference in person today with Jazz Pharmaceuticals.
So this year is a little different than past years. We're not going to switch rooms for Q&A. After the presentation, you can raise your hand. Someone will bring you a mic, or you can use the portal, send me a question on the iPad up here, and I'll ask your question. But with that out of the way, let me turn it over to Jazz' Chairman and CEO, Bruce Cozadd.
Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
All right. So thanks, Jess, and thanks for joining us today. Today starts my 32nd consecutive JPMorgan conference. Hard to believe. I did start young just for the record.
It's my pleasure to be able to present an update on Jazz Pharmaceuticals progress today. During 2022, thanks to the passion and the innovation of our 3,000 talented employees
Jazz Pharmaceuticals PLC at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers